Recent Comments

    Caspase-1/Caspase-6 neurodegenerative pathway tagged posts

    Promising Novel Treatment against Alzheimer’s Disease

    September 26, 2018, Categories  Health/Medical, Biology/Biotechnology

    Casp1 KO restores cognitive function in J20 mice. a−e Genotypes: J20−/−/Casp1−/− WT/WT (grey squares), J20−/−/Casp1+/− WT/Het (pink diamonds), J20−/−/Casp1−/− WT/KO (blue symbol), J20−/+/Casp1+/+ J20/WT (black circles), J20−/+/Casp1−/+ J20/Het (purple triangles), J20−/+/Casp1−/− J20/KO (blue triangles). Each mouse tested is represented by one symbol. Data represent mean and s.e.m. a NOR discrimination index (F(5,67) = 16.22, p < 0.0001) and b distance travelled during open field task (F(5,67) = 3.717, p = 0.005). c−e Barnes maze: c # of primary errors during learning acquisition (Genotype, F(5,263) = 6.469, p < 0.0001; Training day, F(3,263) = 29.44, p < 0.0001), d probe primary latency and errors (Primary errors, F(5,66) = 4.8, p = 0008) and e target preference. a, b, d ANOVA and c two-way ANOVA, Dunnett’s post-hoc versus WT/WT. *p < 0.05, **p < 0.01, ****p < 0.0001

    Casp1 KO restores cognitive function in J20 mice.

    New research conducted at the Lady Davis Institute (LDI) at the Jewish General Hospital reveals that a novel drug reverses memory deficits and stops Alzheimer disease pathology (AD) in an animal model. Importantly, this drug has already proven to be non-toxic for humans in a clinical setting and could, therefore, be brought quickly to trials in humans against AD. These findings are published today in Nature Communications.

    For years, Dr. LeBlanc, Senior Investigator at the LDI and Professor of Neurology and Neurosurgery at McGill University, has strived to identify early neurodegenerative events responsible for age-related memory loss...

    Read More